Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged 522 patent
Coherus denied institution on Enbrel® IPRs – how does that affect Sandoz?

The PTAB has denied institution of two IPRs filed by Coherus Biosciences against patents covering Enbrel®’s proteins, the ‘182 and ‘522 patents.  The IPRs were not filed by Sandoz, but they will most likely affect Sandoz.  Sandoz already has FDA approval to market Erelzi®, which is its biosimilar for Enbrel®.  And Sandoz is going to trial against Amgen in April.  How do Coherus IPR decisions affect Sandoz's decision to launch at risk?  Or to settle with Amgen?

Read More
Markman AdvisorsAmgen, Sandoz, Novartis, Enbrel, Erelzi, biologics, biologic, biosimilar, Coherus Biosciences, FDA, patent, Inter Partes Review, IPR, 182 patent, 522 patent, protein, PTAB, Federal Circuit, Cuozzo Comment